Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Consolidation Therapy With Bortezomib in Patients With Multiple Myeloma Aged 61 to 75
Authors not listed
Janssen-Cilag G.m.b.H · 2006
Abstract
The purpose of this study is to evaluate the efficacy and safety of a consolidation therapy with bortezomib in patients with multiple myeloma aged 61 to 75.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-19 MST
Cite this
APA
Anonymous. (2006). Consolidation Therapy With Bortezomib in Patients With Multiple Myeloma Aged 61 to 75. <em>Janssen-Cilag G.m.b.H</em>. https://clinicaltrials.gov/study/NCT00416208
Vancouver
Anonymous. Consolidation Therapy With Bortezomib in Patients With Multiple Myeloma Aged 61 to 75. Janssen-Cilag G.m.b.H. 2006.
BibTeX
@misc{anon2006Consol,
title = {Consolidation Therapy With Bortezomib in Patients With Multiple Myeloma Aged 61 to 75},
author = {Anonymous},
journal = {Janssen-Cilag G.m.b.H},
year = {2006},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Samsung Medical Center 2020
Open access · US-GOV
Randomized Phase II Study of Bortezomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Elderly Patients With Newly Diagnosed Multiple Myeloma
University of Turin, Italy 2005
Open access · US-GOV
A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients
Beijing Immunochina Medical Science & Technology Co., Ltd. 2020
Open access · US-GOV
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
GeroScience 2026
Citation only
Frailty assessment in naturally aged mouse models: classification, limitations, and future directions
Gruppo Italiano per lo Studio del Mieloma Multiplo 2002
Open access · US-GOV
Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.
Nicola Goekbuget 2018
Open access · US-GOV